Patient Square Capital General Information
Patient Square Capital is a leading healthcare-focused private equity and investment firm. It partners with growth-oriented companies whose products, services, and technologies improve health. The firm's portfolio includes biopharmaceuticals, medical devices, gene therapy developers, healthcare service providers, and enabling technology firms. It manages approximately $11 billion in assets as of September 2024 and has invested in notable companies such as Apollo Therapeutics (biopharma), Alladapt Immunotherapeutics (food allergy therapeutics), CAMP4 Therapeutics (RNA-based therapies), Kriya Therapeutics (gene therapy), Eargo Inc. (hearing device), Hanger Inc. (orthotics/prosthetics), among others.[5][7][3] The firm does not develop drugs or own clinical programs directly but enables innovation through capital deployment. Its subsidiary Enavate Sciences provides capital/strategic support to therapeutic technology companies.[9]
Contact Information
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Co-investments with major institutional investors/funds on deals such as Apollo Therapeutics Series C ($226M+ led by Patient Square); partnerships are typically at the portfolio company level.
Patient Square Capital Funding
No funding data available
Gosset